Literature DB >> 12478896

[Establishment of a cisplatin-induced human hepatocellular carcinoma drug-resistant cell line and its biological characteristics].

Jun-xia Yang1, Wei-xue Tang.   

Abstract

BACKGROUND &
OBJECTIVE: Drug resistance is a popular topic in tumor study. The drug-resistant cell line established in vitro is generally used as the research model. To explore the mechanism of resistance of hepatocellular carcinoma(HCC) to cisplatin, we designed this study to establish a cisplatin-induced human hepatocellular carcinoma drug-resistant cell line and study its characteristics.
METHODS: A resistant HCC cell line (QGY/cDDP) was established gradually by increasing dose of cisplatin and intermittent administration; drug sensitivity was detected by MTT assay; the changes of its biological characteristics were determined using light microscopy, electron microscopy, cell counting, flow cytometry(FCM), and chromatosome analysis.
RESULTS: QGY/cDDP cell line was developed after 3 months with stable resistance to cisplatin and the resistance index was 10.81; QGY/cDDP cells exhibited cross-resistance to many other chemotherapeutic agents (5-Fuorouracil, epiadriamycin, etc). The morphology and chromatosome number of QGY/cDDP changed; doubling time prolonged; and the cell number of S-phase and G2/M-phase decreased while in G0/G1 phase increased compared with parent cells.
CONCLUSION: QGY/cDDP cell line shows the typical and stable resistant phenotype.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12478896

Source DB:  PubMed          Journal:  Ai Zheng


  2 in total

1.  Silence of p15 expression by RNAi enhances cisplatin resistance in hepatocellular carcinoma cells.

Authors:  Dianliang Fang; Yuanhong Guo; Zhenshuang Zhu; Weiqing Chen
Journal:  Bosn J Basic Med Sci       Date:  2012-02       Impact factor: 3.363

2.  Establishment and characterization of human hepatocellular carcinoma cell line FHCC-98.

Authors:  Chao-Yang Lou; Ying-Ming Feng; Ai-Rong Qian; Yu Li; Hao Tang; Peng Shang; Zhi-Nan Chen
Journal:  World J Gastroenterol       Date:  2004-05-15       Impact factor: 5.742

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.